Amneal Pharmaceuticals (NASDAQ:AMRX) Shares Down 7.1%

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) fell 7.1% during trading on Thursday . The company traded as low as $5.59 and last traded at $5.62. 1,801,136 shares changed hands during mid-day trading, an increase of 18% from the average session volume of 1,521,437 shares. The stock had previously closed at $6.05.

Analyst Ratings Changes

A number of brokerages have recently commented on AMRX. The Goldman Sachs Group raised their target price on shares of Amneal Pharmaceuticals from $5.50 to $6.25 and gave the company a “buy” rating in a research note on Monday, March 4th. StockNews.com downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, March 4th. Piper Sandler lifted their price target on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an “overweight” rating in a research note on Thursday, March 21st. Finally, Barclays lifted their price target on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an “overweight” rating in a research note on Monday, January 29th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $7.31.

Amneal Pharmaceuticals Stock Down 0.5 %

The company has a current ratio of 1.63, a quick ratio of 0.94 and a debt-to-equity ratio of 121.31. The company’s fifty day simple moving average is $5.72 and its two-hundred day simple moving average is $5.19.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings data on Friday, March 1st. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.07. The company had revenue of $616.98 million during the quarter, compared to analyst estimates of $630.67 million. Amneal Pharmaceuticals had a negative net margin of 3.51% and a positive return on equity of 126.04%. Equities analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.5 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in shares of Amneal Pharmaceuticals by 3.1% in the 3rd quarter. Vanguard Group Inc. now owns 13,548,300 shares of the company’s stock valued at $57,174,000 after buying an additional 412,599 shares during the period. Rubric Capital Management LP boosted its holdings in shares of Amneal Pharmaceuticals by 98.8% in the 4th quarter. Rubric Capital Management LP now owns 8,000,000 shares of the company’s stock valued at $48,560,000 after buying an additional 3,975,500 shares during the period. LSV Asset Management boosted its holdings in shares of Amneal Pharmaceuticals by 10.5% in the 3rd quarter. LSV Asset Management now owns 1,429,300 shares of the company’s stock valued at $6,032,000 after buying an additional 136,100 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Amneal Pharmaceuticals by 2.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,329,508 shares of the company’s stock valued at $8,070,000 after buying an additional 26,875 shares during the period. Finally, Teacher Retirement System of Texas boosted its holdings in shares of Amneal Pharmaceuticals by 3.4% in the 4th quarter. Teacher Retirement System of Texas now owns 744,752 shares of the company’s stock valued at $4,521,000 after buying an additional 24,651 shares during the period. 31.82% of the stock is owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.